At the time of writing, Humacyte Inc [HUMA] stock is trading at $1.73, up 31.06%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HUMA shares have gain 40.65% over the last week, with a monthly amount glided 13.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $15 from $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 11, 2023, and set its price target to $6. On August 14, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $3.50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on June 22, 2023. Piper Sandler downgraded its rating to a Underweight and reduced its price target to $4 on May 16, 2022. Cowen started tracking with a Outperform rating for this stock on October 29, 2021, and assigned it a price target of $17. In a note dated September 24, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $16 on this stock.
For the past year, the stock price of Humacyte Inc fluctuated between $1.15 and $9.97. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $1.73 at the most recent close of the market. An investor can expect a potential return of 304.62% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.08, Equity is 5.02 and Total Capital is -0.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5333 points at the first support level, and at 1.3367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8633, and for the 2nd resistance point, it is at 1.9967.
Ratios To Look Out For
It is important to note that Humacyte Inc [NASDAQ:HUMA] has a current ratio of 2.40. Further, the Quick Ratio stands at 2.40, while the Cash Ratio is 2.25.
Transactions by insiders
Recent insider trading involved Scheessele William John, Chief Commercial Officer, that happened on Apr 14 ’25 when 6493.0 shares were purchased. CFO and Chief Corp. Deve. Off., Sander Dale A. completed a deal on Apr 10 ’25 to buy 20000.0 shares. Meanwhile, Chief Medical Officer Parikh Shamik J bought 7500.0 shares on Apr 10 ’25.
